Format

Send to

Choose Destination
Blood Purif. 2012;33(1-3):119-24. doi: 10.1159/000334161. Epub 2012 Jan 20.

Mineralocorticoid receptor blockade in chronic kidney disease.

Author information

1
Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.

Abstract

Mineralocorticoid receptor blockers (MRBs) have proven highly successful in the treatment of congestive heart failure and resistant hypertension. In contrast, their use in chronic kidney disease (CKD) has lagged due to the concern of hyperkalemia and, possibly, because of the incorrect assumption that traditional therapy with angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers consistently reduce aldosterone activity in all patients. Low-dose MRB therapy may offer additional antihypertensive and unique anti-inflammatory benefits in select CKD populations.

PMID:
22269185
DOI:
10.1159/000334161
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center